Results 121 to 130 of about 9,061 (176)

Case Report: Colonic metastasis from mixed breast carcinoma masquerading as abemaciclib-associated diarrhea. [PDF]

Front Oncol
Lv L, Wang X, Zhu X.
europepmc   +1 more source

LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma. [PDF]

Sci Adv
Xiao JF, Ko EY, Smith A, Piras R, Fowler A, Ishaya K, Wang L, Wang B, Paulucci-Holthauzen A, Landers SM, Bhalla AD, Torres KE, Shamsutdinova D, Wani KM, Lazar AJ, Keung EZ, Somaiah N, Nassif Haddad EF, Guarnerio J.   +18 more
europepmc   +1 more source

Risk of venous thromboembolism with CDK4/6 inhibitor use in breast cancer: a systematic review and meta-analysis. [PDF]

Oncologist
Cortez E, Torres Luna E, Blancerte Ibarra M, Riojas Suárez IE, Garcia-Perdomo HA, Rojas Hernandez CM.   +5 more
europepmc   +1 more source

Clinical benefit of palbociclib retreatment after abemaciclib exposure in hormone receptor positive, HER2 negative metastatic breast cancer. [PDF]

Sci Rep
Yu M, Yamashita M, Takada M, Takabatake D, Takahashi M, Kochi M, Uno M, Kondo M, Nagashima T, Fujimoto H, Sakakibara J, Teranaka R, Aogi K, Otsuka M.   +13 more
europepmc   +1 more source

Axillary surgery in the cyclin-dependent kinase 4/6 inhibitors era: no time to move backward. [PDF]

Transl Breast Cancer Res
Pla-Farnós MJ, Mension E, Gallegos MI, Sánchez-Méndez JI.   +3 more
europepmc   +1 more source

ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance. [PDF]

Genome Med
Guarducci C, Abravanel D, Russo D, Prasad K, Fu J, Nagy Z, Rao V, Nardone A, Kuang Y, Feit A, Ma W, Feit GC, Hermida-Prado F, Heraud C, Munoz Gomez M, Garcia Cortes DE, Kurnia P, Gomez Tejeda Zanudo J, Li R, Qiu X, Cristea S, Feiglin A, Cheng YC, Lin NU, Tolaney SM, Malorni L, Sicinski P, Polyak K, Paweletz C, Long H, Stewart C, Michor F, Getz G, Brown M, Jeselsohn R.   +34 more
europepmc   +1 more source

Abemaciclib Inhibits Retinoblastoma Tumor Growth by Targeting CDK1/2. [PDF]

Invest Ophthalmol Vis Sci
Yang H, Xiao Q, Shen Y, Yao Y, Yin X, Sang Y, Deng Y.   +6 more
europepmc   +1 more source

Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary. [PDF]

Future Oncol
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A.   +9 more
europepmc   +1 more source

Targeting Aurora A Kinase Enhance the CDK4/6 Inhibitor Sensitivity in HR+/HER2- Breast Cancer. [PDF]

Oncol Res
Wu J, Wang Y, Yan H, Li J, Quan C, Yuan J, Sun S.   +6 more
europepmc   +1 more source

Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study. [PDF]

Pharmacoepidemiol Drug Saf
Rajamaki B, Tenhunen O, Pylkkänen L, Vo T, Paakinaho A, Turpeinen M, Hartikainen S, Tolppanen AM.   +7 more
europepmc   +1 more source